July 24, 2025, Shanghai – Cascade announced that its self-developed Class 1 new drug, the CS0159 oral tablet, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA). Based on CS0159's outstanding clinical potential in treating Primary Biliary Cholangitis (PBC), this achievement signifies a major milestone in its international development.
沪ICP备88888888号